Non-Invasive Diagnostic Technology Creates Unique AI Models for Individual Diseases with Dejan Nenov Luventix TRANSCRIPT

Paul Romness, CEO, President, and Chair of OS Therapies, which is developing an immunotherapy to treat osteosarcoma, a rare bone cancer that stimulates the immune system to identify and eliminate cancer cells. The approach upregulates positive immune factors amd downregulates negative factors resulting in a dual biomarker response and better management of side effects. OS Therapies plans to expand its platform technology to other solid tumors with significant unmet needs, including breast,  esophageal, and colorectal cancer.    Paul explains, "What I think is important is that OS Therapies was started for unmet need, not just in the United States, but there are 20,000 patients a year that get osteosarcoma globally. And it's our responsibility to address patients globally. And it is interesting from a regulatory standpoint, as they start to coordinate with each other, that there are routes for us to get approval in the United States through MHRA, through the UK, and through the collaboration with the EU, with a system called Orbis. But we're also still very confident and very encouraged by the progress we've made with the FDA over the last few months."   "And for OS Therapies, we will pivot to other solid tumors. So our primary mission is osteosarcoma, but once we get approval, we'll pivot to other solid tumors that still have a lot of unmet medical need, like breast cancer. There are still 40,000, mostly women, dying each year of breast cancer, esophageal cancer, or colorectal cancer. So if we can encourage other companies to come into this space, we'll not only achieve our primary mission, but we'll also deliver for patients, which is our goal." #OSTherapies #Osteosarcoma #RareDisease #RareCancer #PediatricOncology #RareDiseaseOncology #SolidTumors #Immunotherapy #ListeriaCancerImmunotherapy #Biomarkers #Oncology #ClinicalTrials #HER2 #CancerResearch #ComparativeOncology#CanineOsteosarcoma ostherapies.com Listen to the podcast here

Paul Romness, CEO, President, and Chair of OS Therapies, which is developing an immunotherapy to treat osteosarcoma, a rare bone cancer that stimulates the immune system to identify and eliminate cancer cells. The approach upregulates positive immune factors amd downregulates negative factors resulting in a dual biomarker response and better management of side effects. OS Therapies plans to expand its platform technology to other solid tumors with significant unmet needs, including breast,  esophageal, and colorectal cancer.    Paul explains, "What I think is important is that OS Therapies was started for unmet need, not just in the United States, but there are 20,000 patients a year that get osteosarcoma globally. And it's our responsibility to address patients globally. And it is interesting from a regulatory standpoint, as they start to coordinate with each other, that there are routes for us to get approval in the United States through MHRA, through the UK, and through the collaboration with the EU, with a system called Orbis. But we're also still very confident and very encouraged by the progress we've made with the FDA over the last few months."   "And for OS Therapies, we will pivot to other solid tumors. So our primary mission is osteosarcoma, but once we get approval, we'll pivot to other solid tumors that still have a lot of unmet medical need, like breast cancer. There are still 40,000, mostly women, dying each year of breast cancer, esophageal cancer, or colorectal cancer. So if we can encourage other companies to come into this space, we'll not only achieve our primary mission, but we'll also deliver for patients, which is our goal." #OSTherapies #Osteosarcoma #RareDisease #RareCancer #PediatricOncology #RareDiseaseOncology #SolidTumors #Immunotherapy #ListeriaCancerImmunotherapy #Biomarkers #Oncology #ClinicalTrials #HER2 #CancerResearch #ComparativeOncology#CanineOsteosarcoma ostherapies.com Download the transcript here

Dejan Nenov is the Founder of Luventix, an AI-powered diagnostic platform that uses machine learning to analyze metabolic data from urine samples to detect multiple diseases and health conditions.  This approach, inspired by the ability of dogs to detect cancer through smell, enables a single non-invasive test to screen for conditions across oncology, neurology, immunology, and other areas at a fraction of the cost of genetic sequencing or blood tests.  The platform has applications in precision medicine, patient stratification for clinical trials, and population-level health screening.     Dejan explains, "The origin story is actually quite fun. One of my two co-founders and I were sitting around his dining table after a day of skiing and watching TV, and we saw dogs smelling urine and sitting down when the urine was from a cancer patient. And so we started thinking, can we reproduce this with technology? And we looked at it and said, "Well, what does the dog's nose do?" And we said, "Well, it's identifying the molecules in the volatiles of the sample, the urine. That looks suspiciously like gas chromatography."   "And then what happens? Well, the dog's brain determines whether the sample is positive or negative. And that's a classifier, a classic classification problem based on a dataset. So we roll back a year or so, and my co-founder Martin did a study to explore whether he could build models to do what the dogs did, but consistently in a mechanistically repeatable fashion."   "We demonstrated that, yes, indeed, based on creating a digital twin of the patient's organism using metabolic data from a urine sample, we're able to train models that can determine whether a disease or condition is present from a urine sample. In the most general case, that's sort of a patient stratification technology." #Luventix #DigitalHealth #PrecisionMedicine #HealthTech #AIinHealthcare #PatientEmpowerment #HealthInnovation #FutureOfHealthcare #DiagnosticInnovation #HealthTechStartup #ConnectedHealth#HealthcareInnovation #AIinHealthcare #Diagnostics #CancerDetection #MedicalAI #ClinicalTrials #Metabolomics #FutureOfMedicine luventix.com  Listen to the podcast here

Dejan Nenov is the Founder of Luventix, an AI-powered diagnostic platform that uses machine learning to analyze metabolic data from urine samples to detect multiple diseases and health conditions.  This approach, inspired by the ability of dogs to detect cancer through smell, enables a single non-invasive test to screen for conditions across oncology, neurology, immunology, and other areas at a fraction of the cost of genetic sequencing or blood tests.  The platform has applications in precision medicine, patient stratification for clinical trials, and population-level health screening.     Dejan explains, "The origin story is actually quite fun. One of my two co-founders and I were sitting around his dining table after a day of skiing and watching TV, and we saw dogs smelling urine and sitting down when the urine was from a cancer patient. And so we started thinking, can we reproduce this with technology? And we looked at it and said, "Well, what does the dog's nose do?" And we said, "Well, it's identifying the molecules in the volatiles of the sample, the urine. That looks suspiciously like gas chromatography."   "And then what happens? Well, the dog's brain determines whether the sample is positive or negative. And that's a classifier, a classic classification problem based on a dataset. So we roll back a year or so, and my co-founder Martin did a study to explore whether he could build models to do what the dogs did, but consistently in a mechanistically repeatable fashion."   "We demonstrated that, yes, indeed, based on creating a digital twin of the patient's organism using metabolic data from a urine sample, we're able to train models that can determine whether a disease or condition is present from a urine sample. In the most general case, that's sort of a patient stratification technology." #Luventix #DigitalHealth #PrecisionMedicine #HealthTech #AIinHealthcare #PatientEmpowerment #HealthInnovation #FutureOfHealthcare #DiagnosticInnovation #HealthTechStartup #ConnectedHealth#HealthcareInnovation #AIinHealthcare #Diagnostics #CancerDetection #MedicalAI #ClinicalTrials #Metabolomics #FutureOfMedicine luventix.com Download the transcript here

Dr. Hansa Bhargava, Chief Clinical Strategy and Innovation Officer at Healio,  discusses the Healio survey of healthcare professionals to understand evolving attitudes toward AI in clinical practice.  While a significant number of clinicians are leaning into AI adoption, significant trust gaps persist regarding accuracy, data privacy and liability concerns. As AI capabilities advance rapidly, healthcare organizations face pressure to adopt these technologies while maintaining rigorous safeguards and establishing clear policies around shadow AI usage and preserving the human-in-the-loop approach. Hansa explains, "Our core mission is really to support and engage doctors and clinicians in the work that they do. To give you a broad viewpoint, there are about two million peer-reviewed publications a year, and doctors, nurses, and clinicians need to stay up to date to deliver the best quality care to patients. And that is sometimes impossible considering the number of hours that they're doing in the clinical setting. So our goal and our vision are to support them by giving them the information right away and sound bites that they can digest quickly and also get to quickly. Because of that vision and mission, we developed Healio AI to make it even faster and more available in a pure format and using good data sources so that they have the information they need for their patients."   "It's almost impossible for anyone to keep up with those changes. They're exponential, as you just said. And yes, that's definitely a concern, but the other concerns are just fundamental issues of accuracy of the AI delivering the right answers, whether it's frontier models or whether it's a model such as developed by Healio. And then also privacy of patients, data privacy, and also legalities in terms of who holds the bag if things go astray." #Healio #HealioAI #DigitalHealth #HealthcareAI #GenAI #MedicalTechnology #HealthcareProfessionals #CME #PointOfCare #MedicalInformation #HealthTech #PhysicianBurnout #ContinuingEducation #HealthcareInnovation #MedicalJournalism #AIinHealthcare Healio.com  Listen to the podcast here

Dr. Hansa Bhargava, Chief Clinical Strategy and Innovation Officer at Healio,  discusses the Healio survey of healthcare professionals to understand evolving attitudes toward AI in clinical practice.  While a significant number of clinicians are leaning into AI adoption, significant trust gaps persist regarding accuracy, data privacy and liability concerns. As AI capabilities advance rapidly, healthcare organizations face pressure to adopt these technologies while maintaining rigorous safeguards and establishing clear policies around shadow AI usage and preserving the human-in-the-loop approach. Hansa explains, "Our core mission is really to support and engage doctors and clinicians in the work that they do. To give you a broad viewpoint, there are about two million peer-reviewed publications a year, and doctors, nurses, and clinicians need to stay up to date to deliver the best quality care to patients. And that is sometimes impossible considering the number of hours that they're doing in the clinical setting. So our goal and our vision are to support them by giving them the information right away and sound bites that they can digest quickly and also get to quickly. Because of that vision and mission, we developed Healio AI to make it even faster and more available in a pure format and using good data sources so that they have the information they need for their patients."   "It's almost impossible for anyone to keep up with those changes. They're exponential, as you just said. And yes, that's definitely a concern, but the other concerns are just fundamental issues of accuracy of the AI delivering the right answers, whether it's frontier models or whether it's a model such as developed by Healio. And then also privacy of patients, data privacy, and also legalities in terms of who holds the bag if things go astray." #Healio #HealioAI #DigitalHealth #HealthcareAI #GenAI #MedicalTechnology #HealthcareProfessionals #CME #PointOfCare #MedicalInformation #HealthTech #PhysicianBurnout #ContinuingEducation #HealthcareInnovation #MedicalJournalism #AIinHealthcare Healio.com  Download the transcript here

Dr. Carl Rothschild, CEO and Founder, and Eddie Brown, COO of Trifecta Light Technologies, discuss the therapeutic applications of red light and near-infrared therapy by bathing the entire body with these specific light wavelengths. The technology has FDA clearance for fat reduction and healing and clinical research indicates efficacy in neurological disorders and musculoskeletal conditions. The devices are user-friendly and have also been shown to support athletes in recovery and the beauty industry for skin health. Dr. Carl explains, "And so what has since subsequently been learned is that this light of both red, and we also use near infrared, which is even more powerful and more healing; what it does is it affects every cell that we can get to in your body. And the more cells we can get to, the better. That's why you want deep-penetrating, medical-grade beds that can penetrate as much as possible to affect as many cells." Eddie elaborates, "With any kind of red light item, usually the bed, the lights, they're FDA registered, which means basically it's an infrared heat source. What we did with our bed, nobody else was able to do this. Not to say that in the future they're not going to, but right now we're kind of ahead of the curve, the only ones who have it. We've had FDA clearance for ours."   #TrifectaLight #RedLightTherapy #Photobiomodulation #MitochondrialHealth #MetabolicHealth #ChronicCare #SportsMedicine #RegenerativeMedicine Trifectalight.com Listen to the podcast here  

Dr. Carl Rothschild, CEO and Founder, and Eddie Brown, COO of Trifecta Light Technologies, discuss the therapeutic applications of red light and near-infrared therapy by bathing the entire body with these specific light wavelengths. The technology has FDA clearance for fat reduction and healing and clinical research indicates efficacy in neurological disorders and musculoskeletal conditions. The devices are user-friendly and have also been shown to support athletes in recovery and the beauty industry for skin health. Dr. Carl explains, "And so what has since subsequently been learned is that this light of both red, and we also use near infrared, which is even more powerful and more healing; what it does is it affects every cell that we can get to in your body. And the more cells we can get to, the better. That's why you want deep-penetrating, medical-grade beds that can penetrate as much as possible to affect as many cells." Eddie elaborates, "With any kind of red light item, usually the bed, the lights, they're FDA registered, which means basically it's an infrared heat source. What we did with our bed, nobody else was able to do this. Not to say that in the future they're not going to, but right now we're kind of ahead of the curve, the only ones who have it. We've had FDA clearance for ours."  #TrifectaLight #RedLightTherapy #Photobiomodulation #MitochondrialHealth #MetabolicHealth #ChronicCare #SportsMedicine #RegenerativeMedicine Trifectalight.com Download the transcript here  

James Sapirstein, CEO of CoCrystal Pharma, is developing a platform of antiviral therapies to treat norovirus, influenza and other viruses.  Norovirus, commonly transmitted on cruise ships and in dormitories, currently lacks effective vaccines or treatments. CoCrystal's oral small-molecule approach aims to treat active infections by reducing viral shedding duration and provide prophylactic prevention using a novel mechanism that targets viral entry points to prevent replication. James explains, "At CoCrystal Pharma, we have a platform of antiviral programs. The first program is for norovirus, and we have another program for influenza A. And then we also have a platform for rhinovirus, which is also many times referred to as the common cold. There's really not much out there."   "Norovirus is commonly known on cruise ships and in dormitories, college dormitories, and really it spreads by touch. That's why, when cruise ships have an outbreak of norovirus, if people haven't washed their hands or they touch an area where someone has touched that area before with active norovirus, they can get infected. And because people touch their faces over a thousand times, literally in a couple of hours, it's easy to transmit the virus."   "But there's also chronic norovirus, which people don't really talk about much because it's mostly in the nursing homes and assisted living areas, where some of these patients really suffer, and they're septic for a very long period of time. And they're not tested to see if they have norovirus because they have so many other health issues that people just aren't tested correctly." "Most antivirals, for the most part, work on the RNA. They cleave off the RNA, or they cleave off the cell membrane so that it doesn't replicate and the virus dies off. For us, it's much more specific. We like to call it a pocket where the virus enters the cell. We design a drug to specifically kill the virus at certain aspects within the virus, and then it doesn't allow it to replicate. And that's the way it's designed." #CoCrystalPharma #Norovirus #Antivirals #DrugDiscovery #InfectiousDiseases cocrystalpharma.com  Listen to the podcast here

James Sapirstein, CEO of CoCrystal Pharma, is developing a platform of antiviral therapies to treat norovirus, influenza and other viruses.  Norovirus, commonly transmitted on cruise ships and in dormitories, currently lacks effective vaccines or treatments. CoCrystal's oral small-molecule approach aims to treat active infections by reducing viral shedding duration and provide prophylactic prevention using a novel mechanism that targets viral entry points to prevent replication. James explains, "At CoCrystal Pharma, we have a platform of antiviral programs. The first program is for norovirus, and we have another program for influenza A. And then we also have a platform for rhinovirus, which is also many times referred to as the common cold. There's really not much out there."   "Norovirus is commonly known on cruise ships and in dormitories, college dormitories, and really it spreads by touch. That's why, when cruise ships have an outbreak of norovirus, if people haven't washed their hands or they touch an area where someone has touched that area before with active norovirus, they can get infected. And because people touch their faces over a thousand times, literally in a couple of hours, it's easy to transmit the virus."   "But there's also chronic norovirus, which people don't really talk about much because it's mostly in the nursing homes and assisted living areas, where some of these patients really suffer, and they're septic for a very long period of time. And they're not tested to see if they have norovirus because they have so many other health issues that people just aren't tested correctly." "Most antivirals, for the most part, work on the RNA. They cleave off the RNA, or they cleave off the cell membrane so that it doesn't replicate and the virus dies off. For us, it's much more specific. We like to call it a pocket where the virus enters the cell. We design a drug to specifically kill the virus at certain aspects within the virus, and then it doesn't allow it to replicate. And that's the way it's designed." #CoCrystalPharma #Norovirus #Antivirals #DrugDiscovery #InfectiousDiseases cocrystalpharma.com Download the transcript here